Bristol-Myers Squibb Company
BMYNext catalyst
mezigdomide
relapsed or refractory multiple myeloma (RRMM), in combination with carfilzomib and dexamethasone (MeziKd)
Get an email about BMY's next catalysts
Track Bristol-Myers Squibb Company (BMY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 20 more upcoming events in our data (Phase 2 readout, Phase 3 readout, company event).See the timeline
22 upcoming, 3 past
Elotuzumab Phase 2 Est. Readout
Estimated primary completion for Elotuzumab trial (NCT02718833) in Multiple Myeloma. Topline data typically follows completion by weeks to months.
SourceNivolumab Phase 2 Est. Readout
Estimated primary completion for Nivolumab trial (NCT04413123) in Papillary Renal Cell Carcinoma. Topline data typically follows completion by weeks to months.
SourceIpilimumab Phase 2 Est. Readout
Estimated primary completion for Ipilimumab trial (NCT03333616) in Genitourinary Cancer. Topline data typically follows completion by weeks to months.
SourceNivolumab in Phase 2 Est. Readout
Estimated primary completion for Nivolumab in trial (NCT05492123) in Uterine Cervical Neoplasms. Topline data typically follows completion by weeks to months.
SourcePhase 3 Results - Cobenfy
For Alzheimer's psychosis. Bristol Myers has extended the ADEPT-2 Phase 3 trial of Cobenfy for Alzheimer's psychosis due to irregularities, pushing the expected data readout from end of 2025 to sometime in 2026.
Other
Bristol Myers Squibb will merge its separate research and development departments into a single unified R&D entity, effective 1 January 2027.
SourceNivolumab Phase 2 Est. Readout
Estimated primary completion for Nivolumab trial (NCT03465592) in Sarcoma. Topline data typically follows completion by weeks to months.
SourceNivolumab Phase 2 Est. Readout
Estimated primary completion for Nivolumab trial (NCT06946797) in Non-Small Cell Lung Cancer. Topline data typically follows completion by weeks to months.
SourceUpcoming FDA decisions
How BMY's past catalysts played out
Market Overview
Stock performance and key metrics
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation (30% of 2025 revenues); nivolumab (Opdivo), used to treat certain types of cancer (21% of 2025 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (6% of 2025 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2025 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (6% of 2025 revenues); ipilimumab (Yervoy), to treat cancer (6% of 2025 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes (5% of 2025 revenues). In 2025, 69% of the company's revenues came from the United States.
WebsiteMilvexian
Ischemic Stroke; Ischemic Attack, Transient
KarXT
Bipolar-I Disorder With Mania or Mania With Mixed Features
Deucravacitinib
Plaque Psoriasis
Vinflunine
Bladder Cancer
Abatacept
Nephrotic Syndrome
Belatacept
Kidney Transplantation
mavacamten
Hypertrophic Cardiomyopathy
stavudine extended-release, lamivudine, efavirenz
HIV Infections
LPV/r +2 NRTIs (Delayed/optional Switch Group)
HIV Infections
Pomalidomide
Multiple Myeloma
vinflunine and best supportive care
Transitional Cell Carcinoma of the Urothelial Tract
paclitaxel (PTX)
Breast Cancer
BMS-986504
Pancreatic Ductal Adenocarcinoma
Ipilimumab
Prostatic Neoplasms, Castration-Resistant
BMS-986393
Relapsed or Refractory Multiple Myeloma (RRMM)
Pegylated interferon alfa-2a (pegIFNα-2a)
Hepatitis C Virus (HCV)
Nivolumab
Recurrent Head and Neck Squamous Cell Carcinoma
Pumitamig
Untreated, Unresectable, or Metastatic Colorectal Cancer
BMS-650032 (Asunaprevir)
Hepatitis C
BMS-790052 (Daclatasvir)
Hepatitis C
Entecavir (ETV)
Hepatitis B
Relatlimab
Lymphoma, Non-Hodgkin
BMS-936558 (Nivolumab)
Melanoma
Entecavir
Chronic Hepatitis B
Lopinavir+ritonavir
HIV Infections
Peginterferon Lambda-1a
Hepatitis C Virus
NKTR-214
Melanoma
Irbesartan/HCTZ
Hypertension
Cetuximab/Erbitux
Head and Neck Cancer
MDX-1379 (gp100) Melanoma Peptide Vaccine
Melanoma
HBI-8000 in combination with nivolumab
Unresectable or Metastatic Melanoma
Intravenous (IV) abatacept
Rheumatoid Arthritis
Apixaban
Deep-Vein Thrombosis
Megestrol acetate
Anorexia
Iza-bren
Non-Small Cell Lung Cancer
DCV/ASV/BMS-791325
Hepatitis C
Lenalidomide
Lymphoma
adefovir
Hepatitis B
Lamivudine (3TC)
HIV Infections
Daclatasvir
Hepatitis C
Efavirenz (EFV)
HIV Infections
Belatacept More Intensive Regimen (MI)
Renal Transplantation
Xanomeline and Trospium Chloride Capsules
Schizophrenia
BMS-791325
Chronic Hepatitis C
Indinavir (IDV)
HIV Infections
peg-interferon alfa-2a
Hepatitis C Virus
Indinavir sulfate
HIV Infections
Elotuzumab (BMS-901608; HuLuc63)
Smoldering Multiple Myeloma
Repotrectinib
Carcinoma, Non-Small-Cell Lung
Sofosbuvir
Hepatitis C
peginterferon alfa-2a
Hepatitis C Virus
Ritonavir (NRV)
HIV Infections
Tanespimycin
Multiple Myeloma
Apremilast
Psoriasis
BMS-986489 (BMS-986012+Nivolumab)
Extensive-Stage Small Cell Lung Cancer
SAR302503
Hematopoietic Neoplasm
Belatacept Less Intensive Regimen (LI)
Renal Transplantation
Entecavir + Tenofovir
Hepatitis B, Chronic
Asunaprevir
Hepatitis C Virus Infection
BMS-986205
Advanced Cancer
Muraglitazar
Diabetes Mellitus
KarX-EC
Alzheimer Disease
metformin HCl
Diabetes Mellitus, Non-Insulin-Dependent
brivanib
Advanced Non-small Cell Lung Cancer
Anti-Tumor Necrosing Factor (TNF) Therapy
Rheumatoid Arthritis
BMS-986278
Pulmonary Fibrosis
oral antibiotics
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have
Nivolumab/rHuPH20
Melanoma
Stavudine
AIDS Dementia Complex
Ozanimod
Colitis, Ulcerative
Topical Dapsone
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have
Tegafur-gimeracil-oteracil potassium
Gastric Cancer
Nivolumab and rHuPH20
Clear Cell Renal Cell Carcinoma
Irbesartan
Congestive Heart Failure
BMS-986165
Ulcerative Colitis
Subcutaneous (SC) abatacept
Rheumatoid Arthritis
ipilimumab (MDX-010, BMS-734016)
Melanoma
Cobimetinib
Advanced or Metastatic Solid Tumors
BMS-582949
Rheumatoid Arthritis, NOS
Lirilumab
CANCER,NOS
BMS-986036
Hepatic Cirrhosis
MDX-1100
Ulcerative Colitis
Nivolumab (BMS-936558)
Melanoma
relatlimab+nivolumab
Melanoma
Cabazitaxel
Metastatic Prostate Neuroendocrine Carcinoma
Ixabepilone
Breast Cancer
Nivolumab + Relatlimab
Melanoma Stage III
Ipilimumab Injection
Prostate Cancer Metastatic
Nitroglycerin (NTG)
Heart Failure
irinotecan + Carboplatin + erbitux
Metastatic Breast Cancer
Nivolumab and Ipilimumab Combination for Prostate Cancer
Advanced Metastatic Cancer
Branebrutinib
Dermatitis, Atopic
Fianlimab
Prostate Cancer
Nivolumab and Ipilimumab and Combination for Metastatic Cancer
Advanced Metastatic Cancer
Nivolumab Combined with Anlotinib
NSCLC Stage IV
Procarbazine
Lymphoma
Navlimetostat
Solid Tumors
Nivolumab plus Relatlimab
Squamous Cell Carcinoma of the Skin
Corticosteroid: Prednisolone
Melanoma
Corticosteroid: Triamcinolone
Melanoma
Ribasphere
Hepatitis C
Nivolumab and surgical resection
Head and Neck Squamous Cell Carcinoma
Relatlimab and nivolumab fixed dose combination (FDC)
Stage II Melanoma
BMS-936558-01
Cervical Cancer
Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Melanoma
Nivolumab Injection
Recurrent and/or Metastatic Platinum-refractory SCCHN
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab
Melanoma
Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Melanoma
GVAX
Previously Treated Metastatic Adenocarcinoma of the Pancreas
Calcium folinate
Lymphoma
Dose Expansion Doublet: Combination of NKTR-214 + nivolumab
Melanoma
Relatlimab (BMS-986016)
Colon Carcinoma
Liso-cel
Lymphoma
Solu-medrol
Leukemia
atazanavir + ritonavir + dolutegravir
HIV-1 Infection
Relatlimab FDC + Nivolumab
Metastatic Triple-negative Breast Cancer
Corticosteroid: Dexamethasone
Melanoma
Corticosteroid: Hydrocortisone
Melanoma
Nivolumab plus Ipilimumab
Bladder Cancer
Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT)
Lymphoma, Non-Hodgkin
Chemotherapy, carboplatin
Glioblastoma
Arlocabtagene Autoleucel
Multiple Myeloma
Corticosteroid: Methylprednisolone
Melanoma
Corticosteroid: Prednisone
Melanoma
Nivolumab Intravenous
Melanoma (Skin)
combination nivolumab and ipilimumab
Carcinoma, Non-Small-Cell Lung
Corticosteroid: Fludrocortisone
Melanoma
Corticosteroid: Meprednisone
Melanoma
INX-08189 Fasted
Hepatitis C
Ipilimumab in
Localized Oesogastric Adenocarcimona
INX-08189
Hepatitis C
Darbeopoetin
MDS (Myelodysplastic Syndrome)
INX-08189 with low-fat meal
Hepatitis C
BMS-986165 Dose B
Active Psoriatic Arthritis
Fedratinib
Myelofibrosis
APX005M
Metastatic Pancreatic Adenocarcinoma
Ipilimumab and nivolumab
Cutaneous Melanoma
Nivolumab and relatlimab
Cutaneous Melanoma
Izalontamab Brengitecan
Carcinoma, Non-Small-Cell Lung
Ipilimumab Nivolumab and relatlimab
Cutaneous Melanoma
Ipilimumab+ Budesonide
Malignant Melanoma
Ipilimumab/Nivolumab
Metastatic Renal Cell Carcinoma
CC-97540
Lupus Erythematosus, Systemic
MDX-010/MDX-010 + Docetaxel
Prostate Cancer
Drugs Nivolumab
Renal Cell Carcinoma, Clear Cell
BMS-986213 (Relatlimab-Nivolumab FDC)
Renal Cell Carcinoma, Clear Cell
Nivolumab, Surgery, Radiotherapy
Squamous Cell Carcinoma of the Oral Cavity
SOX
Gastric Cancer
Relatlimab + Nivolumab
Melanoma
Nivolumab, Surgery, Chemoradiotherapy
Squamous Cell Carcinoma of the Oral Cavity
cabiralizumab
Peripheral T Cell Lymphoma
BMS-650032 (NS3 Protease Inhibitor)
Hepatitis C
Combination of varlilumab and nivolumab
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Nivolumab & Ipilimumab
Prostate Cancer
Galunisertib
Solid Tumor
Pegylated Interferon Lambda (pegIFNλ)
Hepatitis C
PegIFN lambda
Hepatitis B Virus
CCR2/CCR5 dual antagonist
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
5-Fluorouracil (infusional)
Colorectal Cancer (CRC)
CT-322
Colorectal Cancer (CRC)
Nivolumab Monotherapy
Advanced Metastatic Cancer
Ipilimumab, Melphalan and Dactinomycin
Melanoma
Nivolumab/Ipilimumab
Carcinoma, Renal Cell
COM701 in combination with BMS-986207 and nivolumab
Endometrial Neoplasms
Nivolumab/Relatlimab in a fixed dose combination
Cutaneous Squamous Cell Carcinoma
Nivolumab + Ipilimumab
Colorectal Cancer Metastatic
Sorivudine
HIV Infections
BNT327 Dose Level 1 (DL1)
Locally Advanced Breast Cancer
Tetanus vaccine
Advanced Cancer
BMS-986253
Prostate Cancer
DPV-001 vaccine
Advanced Cancer
Combination immunotherapy with Ipilimumab and Nivolumab
Small Cell Lung Cancer
Albumin-bound paclitaxel
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
KRAS vaccine
Pancreatic Ductal Adenocarcinoma
BMS-936558
Hematologic Neoplasms
Adriamycine
Breast Cancer
Neoadjuvant nivolumab
Renal Cell Carcinoma
Dasatinib (BMS-354825)
Acute Myeloid Leukemia
Neoadjuvant relatlimab
Renal Cell Carcinoma
water pill daily
Atherosclerosis
Administration of BMS-986368
Post-Stroke Spasticity
Neoadjuvant ipilimumab
Renal Cell Carcinoma
BMS-813160
Colorectal Cancer
BMS-650032
Chronic Hepatitis C
MDX-010
Prostate Cancer
BMS-986177
Acute Ischemic Stroke
BMS-790052
Hepatitis C Infection
BMS-986178
Advanced Cancer
MDX-060
Hodgkin's Disease
BMS-986213
Gastric Cancer
BMS-770767
Dyslipidemia
Elotuzumab
Multiple Myeloma
Tyrosinase/gp100/MART-1 Peptides
Intraocular Melanoma
Trametinib
Colorectal Cancer
CTLA4Ig/Abatacept
Psoriasis Vulgaris
BMS-931699
Lupus
BMS-741672
Neuropathic Pain
BMS-690514
Breast Cancer
Ticagrelor
Coronary Artery Disease
Oral Azacitidine
Acute Myeloid Leukemia
HNO Donor
Heart Failure
BMS-986207
Non-Small Cell Lung Cancer
BMS-986166
Dermatitis, Atopic
BMS-823778
Diabetes Mellitus, Type 2
Pexacerfont
Major Depressive Disorder
BMS-986016
Hematologic Neoplasms
Platinum Doublet Chemotherapy
Non-Small-Cell Lung Cancer
BMS-986408
Advanced Solid Tumors
Anti-IP-10 Antibody
Colitis, Ulcerative
BMS-986179
Malignant Solid Tumor
Luspatercept
Anemia
BMS-817399
Rheumatoid Arthritis
BMS-954561
Post-Herpetic Neuralgia (PHN)
Nivolumab in
Uterine Cervical Neoplasms
antithymocyte globulin (rabbit)
Living-Donor Kidney Transplant
rHuPH20
Neoplasms by Site
BMS-986158
Advanced Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Milvexian | Phase 3 | Ischemic Stroke; Ischemic Attack, Transient | - | - |
KarXT | Phase 3 | Bipolar-I Disorder With Mania or Mania With Mixed Features | - | - |
Deucravacitinib | Phase 3 | Plaque Psoriasis | - | - |
Vinflunine | Phase 3 | Bladder Cancer | - | - |
Abatacept | Phase 3 | Nephrotic Syndrome | - | - |
Belatacept | Phase 3 | Kidney Transplantation | - | - |
mavacamten | Phase 3 | Hypertrophic Cardiomyopathy | - | - |
stavudine extended-release, lamivudine, efavirenz | Phase 3 | HIV Infections | - | - |
LPV/r +2 NRTIs (Delayed/optional Switch Group) | Phase 3 | HIV Infections | - | - |
Pomalidomide | Phase 3 | Multiple Myeloma | - | - |
vinflunine and best supportive care | Phase 3 | Transitional Cell Carcinoma of the Urothelial Tract | - | - |
paclitaxel (PTX) | Phase 3 | Breast Cancer | - | - |
BMS-986504 | Phase 3 | Pancreatic Ductal Adenocarcinoma | - | - |
Ipilimumab | Phase 3 | Prostatic Neoplasms, Castration-Resistant | - | - |
BMS-986393 | Phase 3 | Relapsed or Refractory Multiple Myeloma (RRMM) | - | - |
Pegylated interferon alfa-2a (pegIFNα-2a) | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Nivolumab | Phase 3 | Recurrent Head and Neck Squamous Cell Carcinoma | - | - |
Pumitamig | Phase 3 | Untreated, Unresectable, or Metastatic Colorectal Cancer | - | - |
BMS-650032 (Asunaprevir) | Phase 3 | Hepatitis C | - | - |
BMS-790052 (Daclatasvir) | Phase 3 | Hepatitis C | - | - |
Entecavir (ETV) | Phase 3 | Hepatitis B | - | - |
Relatlimab | Phase 3 | Lymphoma, Non-Hodgkin | - | - |
BMS-936558 (Nivolumab) | Phase 3 | Melanoma | - | - |
Entecavir | Phase 3 | Chronic Hepatitis B | - | - |
Lopinavir+ritonavir | Phase 3 | HIV Infections | - | - |
Peginterferon Lambda-1a | Phase 3 | Hepatitis C Virus | - | - |
NKTR-214 | Phase 3 | Melanoma | - | - |
Irbesartan/HCTZ | Phase 3 | Hypertension | - | - |
Cetuximab/Erbitux | Phase 3 | Head and Neck Cancer | - | - |
MDX-1379 (gp100) Melanoma Peptide Vaccine | Phase 3 | Melanoma | - | - |
HBI-8000 in combination with nivolumab | Phase 3 | Unresectable or Metastatic Melanoma | - | - |
Intravenous (IV) abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
Apixaban | Phase 3 | Deep-Vein Thrombosis | - | - |
Megestrol acetate | Phase 3 | Anorexia | - | - |
Iza-bren | Phase 3 | Non-Small Cell Lung Cancer | - | - |
DCV/ASV/BMS-791325 | Phase 3 | Hepatitis C | - | - |
Lenalidomide | Phase 3 | Lymphoma | - | - |
adefovir | Phase 3 | Hepatitis B | - | - |
Lamivudine (3TC) | Phase 3 | HIV Infections | - | - |
Daclatasvir | Phase 3 | Hepatitis C | - | - |
Efavirenz (EFV) | Phase 3 | HIV Infections | - | - |
Belatacept More Intensive Regimen (MI) | Phase 3 | Renal Transplantation | - | - |
Xanomeline and Trospium Chloride Capsules | Phase 3 | Schizophrenia | - | - |
BMS-791325 | Phase 3 | Chronic Hepatitis C | - | - |
Indinavir (IDV) | Phase 3 | HIV Infections | - | - |
peg-interferon alfa-2a | Phase 3 | Hepatitis C Virus | - | - |
Indinavir sulfate | Phase 3 | HIV Infections | - | - |
Elotuzumab (BMS-901608; HuLuc63) | Phase 3 | Smoldering Multiple Myeloma | - | - |
Repotrectinib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Sofosbuvir | Phase 3 | Hepatitis C | - | - |
peginterferon alfa-2a | Phase 3 | Hepatitis C Virus | - | - |
Ritonavir (NRV) | Phase 3 | HIV Infections | - | - |
Tanespimycin | Phase 3 | Multiple Myeloma | - | - |
Apremilast | Phase 3 | Psoriasis | - | - |
BMS-986489 (BMS-986012+Nivolumab) | Phase 3 | Extensive-Stage Small Cell Lung Cancer | - | - |
SAR302503 | Phase 3 | Hematopoietic Neoplasm | - | - |
Belatacept Less Intensive Regimen (LI) | Phase 3 | Renal Transplantation | - | - |
Entecavir + Tenofovir | Phase 3 | Hepatitis B, Chronic | - | - |
Asunaprevir | Phase 3 | Hepatitis C Virus Infection | - | - |
BMS-986205 | Phase 3 | Advanced Cancer | - | - |
Muraglitazar | Phase 3 | Diabetes Mellitus | - | - |
KarX-EC | Phase 3 | Alzheimer Disease | - | - |
metformin HCl | Phase 3 | Diabetes Mellitus, Non-Insulin-Dependent | - | - |
brivanib | Phase 3 | Advanced Non-small Cell Lung Cancer | - | - |
Anti-Tumor Necrosing Factor (TNF) Therapy | Phase 3 | Rheumatoid Arthritis | - | - |
BMS-986278 | Phase 3 | Pulmonary Fibrosis | - | - |
oral antibiotics | Phase 3 | Cetuximab-induced Papulopustular (Acneiform) Rash Who Have | - | - |
Nivolumab/rHuPH20 | Phase 3 | Melanoma | - | - |
Stavudine | Phase 3 | AIDS Dementia Complex | - | - |
Ozanimod | Phase 3 | Colitis, Ulcerative | - | - |
Topical Dapsone | Phase 3 | Cetuximab-induced Papulopustular (Acneiform) Rash Who Have | - | - |
Tegafur-gimeracil-oteracil potassium | Phase 3 | Gastric Cancer | - | - |
Nivolumab and rHuPH20 | Phase 3 | Clear Cell Renal Cell Carcinoma | - | - |
Irbesartan | Phase 3 | Congestive Heart Failure | - | - |
BMS-986165 | Phase 3 | Ulcerative Colitis | - | - |
Subcutaneous (SC) abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
ipilimumab (MDX-010, BMS-734016) | Phase 2 | Melanoma | - | - |
Cobimetinib | Phase 2 | Advanced or Metastatic Solid Tumors | - | - |
BMS-582949 | Phase 2 | Rheumatoid Arthritis, NOS | - | - |
Lirilumab | Phase 2 | CANCER,NOS | - | - |
BMS-986036 | Phase 2 | Hepatic Cirrhosis | - | - |
MDX-1100 | Phase 2 | Ulcerative Colitis | - | - |
Nivolumab (BMS-936558) | Phase 2 | Melanoma | - | - |
relatlimab+nivolumab | Phase 2 | Melanoma | - | - |
Cabazitaxel | Phase 2 | Metastatic Prostate Neuroendocrine Carcinoma | - | - |
Ixabepilone | Phase 2 | Breast Cancer | - | - |
Nivolumab + Relatlimab | Phase 2 | Melanoma Stage III | - | - |
Ipilimumab Injection | Phase 2 | Prostate Cancer Metastatic | - | - |
Nitroglycerin (NTG) | Phase 2 | Heart Failure | - | - |
irinotecan + Carboplatin + erbitux | Phase 2 | Metastatic Breast Cancer | - | - |
Nivolumab and Ipilimumab Combination for Prostate Cancer | Phase 2 | Advanced Metastatic Cancer | - | - |
Branebrutinib | Phase 2 | Dermatitis, Atopic | - | - |
Fianlimab | Phase 2 | Prostate Cancer | - | - |
Nivolumab and Ipilimumab and Combination for Metastatic Cancer | Phase 2 | Advanced Metastatic Cancer | - | - |
Nivolumab Combined with Anlotinib | Phase 2 | NSCLC Stage IV | - | - |
Procarbazine | Phase 2 | Lymphoma | - | - |
Navlimetostat | Phase 2 | Solid Tumors | - | - |
Nivolumab plus Relatlimab | Phase 2 | Squamous Cell Carcinoma of the Skin | - | - |
Corticosteroid: Prednisolone | Phase 2 | Melanoma | - | - |
Corticosteroid: Triamcinolone | Phase 2 | Melanoma | - | - |
Ribasphere | Phase 2 | Hepatitis C | - | - |
Nivolumab and surgical resection | Phase 2 | Head and Neck Squamous Cell Carcinoma | - | - |
Relatlimab and nivolumab fixed dose combination (FDC) | Phase 2 | Stage II Melanoma | - | - |
BMS-936558-01 | Phase 2 | Cervical Cancer | - | - |
Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab | Phase 2 | Melanoma | - | - |
Nivolumab Injection | Phase 2 | Recurrent and/or Metastatic Platinum-refractory SCCHN | - | - |
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab | Phase 2 | Melanoma | - | - |
Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab | Phase 2 | Melanoma | - | - |
GVAX | Phase 2 | Previously Treated Metastatic Adenocarcinoma of the Pancreas | - | - |
Calcium folinate | Phase 2 | Lymphoma | - | - |
Dose Expansion Doublet: Combination of NKTR-214 + nivolumab | Phase 2 | Melanoma | - | - |
Relatlimab (BMS-986016) | Phase 2 | Colon Carcinoma | - | - |
Liso-cel | Phase 2 | Lymphoma | - | - |
Solu-medrol | Phase 2 | Leukemia | - | - |
atazanavir + ritonavir + dolutegravir | Phase 2 | HIV-1 Infection | - | - |
Relatlimab FDC + Nivolumab | Phase 2 | Metastatic Triple-negative Breast Cancer | - | - |
Corticosteroid: Dexamethasone | Phase 2 | Melanoma | - | - |
Corticosteroid: Hydrocortisone | Phase 2 | Melanoma | - | - |
Nivolumab plus Ipilimumab | Phase 2 | Bladder Cancer | - | - |
Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT) | Phase 2 | Lymphoma, Non-Hodgkin | - | - |
Chemotherapy, carboplatin | Phase 2 | Glioblastoma | - | - |
Arlocabtagene Autoleucel | Phase 2 | Multiple Myeloma | - | - |
Corticosteroid: Methylprednisolone | Phase 2 | Melanoma | - | - |
Corticosteroid: Prednisone | Phase 2 | Melanoma | - | - |
Nivolumab Intravenous | Phase 2 | Melanoma (Skin) | - | - |
combination nivolumab and ipilimumab | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Corticosteroid: Fludrocortisone | Phase 2 | Melanoma | - | - |
Corticosteroid: Meprednisone | Phase 2 | Melanoma | - | - |
INX-08189 Fasted | Phase 2 | Hepatitis C | - | - |
Ipilimumab in | Phase 2 | Localized Oesogastric Adenocarcimona | - | - |
INX-08189 | Phase 2 | Hepatitis C | - | - |
Darbeopoetin | Phase 2 | MDS (Myelodysplastic Syndrome) | - | - |
INX-08189 with low-fat meal | Phase 2 | Hepatitis C | - | - |
BMS-986165 Dose B | Phase 2 | Active Psoriatic Arthritis | - | - |
Fedratinib | Phase 2 | Myelofibrosis | - | - |
APX005M | Phase 2 | Metastatic Pancreatic Adenocarcinoma | - | - |
Ipilimumab and nivolumab | Phase 2 | Cutaneous Melanoma | - | - |
Nivolumab and relatlimab | Phase 2 | Cutaneous Melanoma | - | - |
Izalontamab Brengitecan | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Ipilimumab Nivolumab and relatlimab | Phase 2 | Cutaneous Melanoma | - | - |
Ipilimumab+ Budesonide | Phase 2 | Malignant Melanoma | - | - |
Ipilimumab/Nivolumab | Phase 2 | Metastatic Renal Cell Carcinoma | - | - |
CC-97540 | Phase 2 | Lupus Erythematosus, Systemic | - | - |
MDX-010/MDX-010 + Docetaxel | Phase 2 | Prostate Cancer | - | - |
Drugs Nivolumab | Phase 2 | Renal Cell Carcinoma, Clear Cell | - | - |
BMS-986213 (Relatlimab-Nivolumab FDC) | Phase 2 | Renal Cell Carcinoma, Clear Cell | - | - |
Nivolumab, Surgery, Radiotherapy | Phase 2 | Squamous Cell Carcinoma of the Oral Cavity | - | - |
SOX | Phase 2 | Gastric Cancer | - | - |
Relatlimab + Nivolumab | Phase 2 | Melanoma | - | - |
Nivolumab, Surgery, Chemoradiotherapy | Phase 2 | Squamous Cell Carcinoma of the Oral Cavity | - | - |
cabiralizumab | Phase 2 | Peripheral T Cell Lymphoma | - | - |
BMS-650032 (NS3 Protease Inhibitor) | Phase 2 | Hepatitis C | - | - |
Combination of varlilumab and nivolumab | Phase 2 | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | - | - |
Nivolumab & Ipilimumab | Phase 2 | Prostate Cancer | - | - |
Galunisertib | Phase 2 | Solid Tumor | - | - |
Pegylated Interferon Lambda (pegIFNλ) | Phase 2 | Hepatitis C | - | - |
PegIFN lambda | Phase 2 | Hepatitis B Virus | - | - |
CCR2/CCR5 dual antagonist | Phase 2 | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) | - | - |
5-Fluorouracil (infusional) | Phase 2 | Colorectal Cancer (CRC) | - | - |
CT-322 | Phase 2 | Colorectal Cancer (CRC) | - | - |
Nivolumab Monotherapy | Phase 2 | Advanced Metastatic Cancer | - | - |
Ipilimumab, Melphalan and Dactinomycin | Phase 2 | Melanoma | - | - |
Nivolumab/Ipilimumab | Phase 2 | Carcinoma, Renal Cell | - | - |
COM701 in combination with BMS-986207 and nivolumab | Phase 2 | Endometrial Neoplasms | - | - |
Nivolumab/Relatlimab in a fixed dose combination | Phase 2 | Cutaneous Squamous Cell Carcinoma | - | - |
Nivolumab + Ipilimumab | Phase 2 | Colorectal Cancer Metastatic | - | - |
Sorivudine | Phase 2 | HIV Infections | - | - |
BNT327 Dose Level 1 (DL1) | Phase 2 | Locally Advanced Breast Cancer | - | - |
Tetanus vaccine | Phase 2 | Advanced Cancer | - | - |
BMS-986253 | Phase 2 | Prostate Cancer | - | - |
DPV-001 vaccine | Phase 2 | Advanced Cancer | - | - |
Combination immunotherapy with Ipilimumab and Nivolumab | Phase 2 | Small Cell Lung Cancer | - | - |
Albumin-bound paclitaxel | Phase 2 | Untreated Metastatic Pancreatic Ductal Adenocarcinoma | - | - |
KRAS vaccine | Phase 2 | Pancreatic Ductal Adenocarcinoma | - | - |
BMS-936558 | Phase 2 | Hematologic Neoplasms | - | - |
Adriamycine | Phase 2 | Breast Cancer | - | - |
Neoadjuvant nivolumab | Phase 2 | Renal Cell Carcinoma | - | - |
Dasatinib (BMS-354825) | Phase 2 | Acute Myeloid Leukemia | - | - |
Neoadjuvant relatlimab | Phase 2 | Renal Cell Carcinoma | - | - |
water pill daily | Phase 2 | Atherosclerosis | - | - |
Administration of BMS-986368 | Phase 2 | Post-Stroke Spasticity | - | - |
Neoadjuvant ipilimumab | Phase 2 | Renal Cell Carcinoma | - | - |
BMS-813160 | Phase 2 | Colorectal Cancer | - | - |
BMS-650032 | Phase 2 | Chronic Hepatitis C | - | - |
MDX-010 | Phase 2 | Prostate Cancer | - | - |
BMS-986177 | Phase 2 | Acute Ischemic Stroke | - | - |
BMS-790052 | Phase 2 | Hepatitis C Infection | - | - |
BMS-986178 | Phase 2 | Advanced Cancer | - | - |
MDX-060 | Phase 2 | Hodgkin's Disease | - | - |
BMS-986213 | Phase 2 | Gastric Cancer | - | - |
BMS-770767 | Phase 2 | Dyslipidemia | - | - |
Elotuzumab | Phase 2 | Multiple Myeloma | - | - |
Tyrosinase/gp100/MART-1 Peptides | Phase 2 | Intraocular Melanoma | - | - |
Trametinib | Phase 2 | Colorectal Cancer | - | - |
CTLA4Ig/Abatacept | Phase 2 | Psoriasis Vulgaris | - | - |
BMS-931699 | Phase 2 | Lupus | - | - |
BMS-741672 | Phase 2 | Neuropathic Pain | - | - |
BMS-690514 | Phase 2 | Breast Cancer | - | - |
Ticagrelor | Phase 2 | Coronary Artery Disease | - | - |
Oral Azacitidine | Phase 2 | Acute Myeloid Leukemia | - | - |
HNO Donor | Phase 2 | Heart Failure | - | - |
BMS-986207 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
BMS-986166 | Phase 2 | Dermatitis, Atopic | - | - |
BMS-823778 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Pexacerfont | Phase 2 | Major Depressive Disorder | - | - |
BMS-986016 | Phase 2 | Hematologic Neoplasms | - | - |
Platinum Doublet Chemotherapy | Phase 2 | Non-Small-Cell Lung Cancer | - | - |
BMS-986408 | Phase 2 | Advanced Solid Tumors | - | - |
Anti-IP-10 Antibody | Phase 2 | Colitis, Ulcerative | - | - |
BMS-986179 | Phase 2 | Malignant Solid Tumor | - | - |
Luspatercept | Phase 2 | Anemia | - | - |
BMS-817399 | Phase 2 | Rheumatoid Arthritis | - | - |
BMS-954561 | Phase 2 | Post-Herpetic Neuralgia (PHN) | - | - |
Nivolumab in | Phase 2 | Uterine Cervical Neoplasms | - | - |
antithymocyte globulin (rabbit) | Phase 2 | Living-Donor Kidney Transplant | - | - |
rHuPH20 | Phase 2 | Neoplasms by Site | - | - |
BMS-986158 | Phase 2 | Advanced Tumors | - | - |
multiple myeloma
4 drugs in this indication
multiple sclerosis
2 drugs in this indication
Alzheimer's
1 drug in this indication
Lupus Erythematosus, Systemic
1 drug in this indication
advanced melanoma
1 drug in this indication
blood cancer
1 drug in this indication
Duchenne muscular dystrophy
1 drug in this indication
multiple myeloma (relapsed or refractory)
1 drug in this indication
Relapsed/refractory multiple myeloma
1 drug in this indication
Alzheimer's psychosis
1 drug in this indication
symptomatic oHCM in adults and paediatric patients weighing at least 30 kg
1 drug in this indication
advanced hepatocellular carcinoma
1 drug in this indication
cardiovascular
1 drug in this indication
lung disease
1 drug in this indication
cancer
1 drug in this indication
pulmonary fibrosis
1 drug in this indication
EBV-positive PTLD
1 drug in this indication
Lupus
1 drug in this indication
systemic lupus erythematosus (SLE); cutaneous lupus erythematosus (CLE)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Bristol-Myers Squibb Company's drug pipeline?→
CatalystAlert tracks 217 drug candidates in Bristol-Myers Squibb Company's (BMY) pipeline across Phase 3, Phase 2. Its lead program is Nivolumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Bristol-Myers Squibb Company's next FDA catalyst?→
Bristol-Myers Squibb Company's (BMY) next tracked catalyst is a PDUFA date expected May 13, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BMY biotech catalysts?→
Add BMY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Bristol-Myers Squibb Company's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
